+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hereditary Testing Market by Disease Type, Technology, Application, End-User - Global Forecast 2025-2030- Product Image
Hereditary Testing Market by Disease Type, Technology, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Hereditary Testing Market by Disease Type, Technology, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5306608
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hereditary Testing Market grew from USD 5.15 billion in 2023 to USD 5.57 billion in 2024. It is expected to continue growing at a CAGR of 8.17%, reaching USD 8.93 billion by 2030.

Hereditary testing, a branch of genetic testing, analyzes DNA to identify risks for inherited diseases, providing valuable health insights. Its necessity has grown as it enables early detection and management of genetic conditions, facilitating personalized medicine approaches. Applications are diverse, spanning prenatal screening, cancer risk assessment, and genetic disorder diagnosis. End-users include healthcare providers, research institutions, and direct-to-consumer services. The market for hereditary testing is influenced by several growth factors, including advancements in genomic technology, rising awareness about personalized medicine, and increasing healthcare expenditure across the globe. Additionally, the shift towards preventive healthcare and the integration of artificial intelligence in genetic testing enhance market attraction. However, challenges such as ethical and privacy concerns, regulatory hurdles, and the high cost of testing may impede growth. Data privacy remains a sensitive area, urging developers to prioritize robust, compliant systems to earn consumer trust. Opportunities lie in expanding service accessibility through online platforms and partnerships with healthcare providers, with emphasis on comprehensive, affordable testing packages. Companies could innovate by developing more accurate and faster testing techniques or leveraging AI to refine predictive models for genetic conditions. The market's future could also benefit from advancements in CRISPR and other gene-editing technologies, presenting potential areas for research. Innovations in telemedicine and integration with electronic health records could further streamline hereditary testing processes, providing a competitive edge. Despite these advancements, navigating regulatory landscapes and gaining public confidence remain imperative to successful market penetration and expansion. Organizations should invest in educational campaigns to foster awareness and understanding, emphasizing the benefits of early detection and personalized care. Leveraging technological innovations and addressing ethical concerns will strengthen market position, driving growth in an evolving healthcare landscape.

Understanding Market Dynamics in the Hereditary Testing Market

The Hereditary Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Exploration for changes or variants, in DNA to find root cause of potential disease
    • Increased screening by pregnant women
    • Rising R&D activities on advance Genome sequencing
  • Market Restraints
    • Limited reimbursement policies
  • Market Opportunities
    • Collaborative product development
    • Attractive investment and amalgamation activity within value chain
  • Market Challenges
    • Uncertain outcomes of the hereditary testing

Exploring Porter’s Five Forces for the Hereditary Testing Market

Porter’s Five Forces framework further strengthens the insights of the Hereditary Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Hereditary Testing Market

External macro-environmental factors deeply influence the performance of the Hereditary Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Hereditary Testing Market

The Hereditary Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Hereditary Testing Market

The Hereditary Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Hereditary Testing Market

The Hereditary Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.

Market Segmentation & Coverage

This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Hereditary Cancer Testing
      • Breast Cancer
      • Cervical Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Melanoma
      • Ovarian Cancer
      • Pancreatic Cancer
      • Prostate Cancer
      • Sarcoma
      • Stomach or Gastric Cancer
      • Uterine Cancer
    • Hereditary Non-Cancer Testing
      • Genetic Tests
        • Cardiac Diseases
        • Rare Diseases
    • Newborn Genetic Screening
    • Non-Invasive Prenatal Testing & Carrier Screening Tests
    • Preimplantation Genetic Diagnosis & Screening
  • Technology
    • Biochemical
    • Cytogenetic
    • Molecular Testing
  • Application
    • Cancer Diagnosis
    • Cardiovascular Disease Diagnosis
    • Genetic Disease Diagnosis
  • End-User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hereditary Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
5.1.1.2. Increased screening by pregnant women
5.1.1.3. Rising R&D activities on advance Genome sequencing
5.1.2. Restraints
5.1.2.1. Limited reimbursement policies
5.1.3. Opportunities
5.1.3.1. Collaborative product development
5.1.3.2. Attractive investment and amalgamation activity within value chain
5.1.4. Challenges
5.1.4.1. Uncertain outcomes of the hereditary testing
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hereditary Testing Market, by Disease Type
6.1. Introduction
6.2. Hereditary Cancer Testing
6.3.1. Breast Cancer
6.3.2. Cervical Cancer
6.3.3. Colorectal Cancer
6.3.4. Lung Cancer
6.3.5. Melanoma
6.3.6. Ovarian Cancer
6.3.7. Pancreatic Cancer
6.3.8. Prostate Cancer
6.3.9. Sarcoma
6.3.10. Stomach or Gastric Cancer
6.3.11. Uterine Cancer
6.3. Hereditary Non-Cancer Testing
6.4.1. Genetic Tests
6.4.2.1. Cardiac Diseases
6.4.2.2. Rare Diseases
6.4. Newborn Genetic Screening
6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
6.6. Preimplantation Genetic Diagnosis & Screening
7. Hereditary Testing Market, by Technology
7.1. Introduction
7.2. Biochemical
7.3. Cytogenetic
7.4. Molecular Testing
8. Hereditary Testing Market, by Application
8.1. Introduction
8.2. Cancer Diagnosis
8.3. Cardiovascular Disease Diagnosis
8.4. Genetic Disease Diagnosis
9. Hereditary Testing Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Hospitals
10. Americas Hereditary Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hereditary Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Hereditary Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. BGI Genomics Co., Ltd.
14.1.2. Biocartis NV
14.1.3. CENTOGENE N.V.
14.1.4. CooperSurgical, Inc.
14.1.5. CSL Behring
14.1.6. Eurofins Scientific SE
14.1.7. F. Hoffmann-La Roche Ltd.
14.1.8. Invitae Corporation
14.1.9. Konica Minolta, Inc.
14.1.10. Medgenome
14.1.11. Myriad Genetics, Inc.
14.1.12. Natera Inc.
14.1.13. Quest Diagnostics Incorporated
14.1.14. Siemens Healthineers AG
14.1.15. SOPHiA Genetics
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEREDITARY TESTING MARKET DYNAMICS
FIGURE 7. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 6. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 8. HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HEREDITARY TESTING MARKET SIZE, BY STOMACH OR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 21. HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 23. HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING & CARRIER SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 29. HEREDITARY TESTING MARKET SIZE, BY BIOCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. HEREDITARY TESTING MARKET SIZE, BY CYTOGENETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. HEREDITARY TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. HEREDITARY TESTING MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. HEREDITARY TESTING MARKET SIZE, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. HEREDITARY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. HEREDITARY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 63. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 64. CANADA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 65. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 70. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 71. MEXICO HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 100. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 101. CHINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 102. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. CHINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 107. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 108. INDIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 109. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. INDIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 121. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 122. JAPAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 123. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. JAPAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. TAIWAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 162. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 163. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 164. THAILAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 165. THAILAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. THAILAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. THAILAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. VIETNAM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. DENMARK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 184. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 185. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 186. DENMARK HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 187. DENMARK HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. DENMARK HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. EGYPT HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 192. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 193. EGYPT HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 194. EGYPT HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. EGYPT HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 199. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 200. FINLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. FINLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. FINLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 205. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 206. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 207. FRANCE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. FRANCE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 213. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 214. GERMANY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 215. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. GERMANY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. ISRAEL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 227. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 228. ITALY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 229. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. ITALY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. NORWAY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 248. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 249. NORWAY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 250. NORWAY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. NORWAY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. NORWAY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 255. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 256. POLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 257. POLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. POLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. POLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 261. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 262. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 263. QATAR HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 264. QATAR HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. QATAR HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. QATAR HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 290. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 291. SPAIN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 293. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. SPAIN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 302. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. TURKEY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 310. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 311. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 312. TURKEY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 313. TURKEY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. TURKEY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 315. TURKEY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 330. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 331. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 332. HEREDITARY TESTING MARKET LICENSE & PRICING

Companies Mentioned

The leading players in the Hereditary Testing Market, which are profiled in this report, include:
  • BGI Genomics Co., Ltd.
  • Biocartis NV
  • CENTOGENE N.V.
  • CooperSurgical, Inc.
  • CSL Behring
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Invitae Corporation
  • Konica Minolta, Inc.
  • Medgenome
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SOPHiA Genetics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.93 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Hereditary Testing - Global Strategic Business Report - Product Image

Hereditary Testing - Global Strategic Business Report

  • Report
  • 92 Pages
  • Global
From
Diagnostic Pathology: Familial Cancer Syndromes. Edition No. 2 - Product Image

Diagnostic Pathology: Familial Cancer Syndromes. Edition No. 2

  • Book
In Vitro Diagnostics Quality Control Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 - Product Image

In Vitro Diagnostics Quality Control Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • Report
  • 178 Pages
  • Global
From
In Vitro Diagnostics Market - Forecasts from 2024 to 2029 - Product Image

In Vitro Diagnostics Market - Forecasts from 2024 to 2029

  • Report
  • 155 Pages
  • Global
From
In Vitro Diagnostic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

In Vitro Diagnostic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 186 Pages
  • Global
From

About the Hereditary Testing Market

The Hereditary Testing market within the context of Diagnostics is a rapidly growing field of medical research. It involves the use of genetic testing to identify inherited diseases and conditions, as well as to assess the risk of developing certain diseases. This type of testing can be used to diagnose a wide range of conditions, including cancer, heart disease, and neurological disorders. It can also be used to identify genetic mutations that may be associated with certain diseases. Hereditary testing is becoming increasingly popular as a way to identify and manage inherited diseases. It is also being used to identify genetic markers that may be associated with certain diseases, such as Alzheimer's and Parkinson's. This type of testing can provide valuable information to help guide treatment decisions and improve patient outcomes. Some of the companies in the Hereditary Testing market include 23andMe, AncestryDNA, MyHeritage, and Helix. These companies offer a variety of services, including genetic testing, ancestry testing, and health-related services. They also provide access to a wide range of genetic data, which can be used to identify inherited diseases and conditions. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.